Found "AI": 1,181 results
Sort by
Sort by
Z - A
AstraZeneca starts new study of heart drug versus rival
(Reuters) – AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain’s second biggest drugmaker said on Tuesday.Peripheral artery disease affects around 27 million people in Europe and North America, with s
Association between ambient temperature and genitourinary mortality in Thailand: a nationwide ecological time-series study
Climate change is increasing the frequency, intensity, and duration of extreme heat events worldwide, posing growing risks to human health. Heat exposure has been linked to adverse kidney outcomes through dehydration, reduced kidney perfusion, electrolyte imbalance, and increased risk of acute kidney injury. While international evidence suggests th
Assessment of HTA capacity in Africa
HITAP, in collaboration with the Center for the Evaluation of Value and Risk in Health, Tufts Medical Cent, conducted an analysis of existing capacity for conducting economic evaluations in the African region using the Tufts Medical Center CEA Registries. The findings of the study were presented at the PMAC 2020 side meeting “Attain & Sustain
Assessment of Health Technology Assessment Capacity in Africa
HITAP, in collaboration with the Center for the Evaluation of Value and Risk in Health, Tufts Medical Cent, conducted an analysis of existing capacity for conducting economic evaluations in the African region using the Tufts Medical Center CEA Registries. The findings of the study were presented at the PMAC 2020 side meeting “Attain & Sustain
Assessment of Capacity Building of Member States of WHO South-East Asia Region in Global Health
The term “global health” has emerged as part of the larger political and historical process, replacing the term “international health” to imply a shared global responsibility for health and is also associated with the growing number and increased roles of other actors beyond governments. In September 2009, Director-General of WHO, in consul
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Abstract
Background and Objectives
The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Abstract
Background and Objectives
The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
10 / Page